```html

Neutrophilic Dermatosis – Comprehensive Medical Guide

Overview

Neutrophilic dermatoses are a group of rare, inflammatory skin disorders characterized by the dense infiltration of neutrophils (a type of white blood cell) into the skin without an obvious infection. The most well‑known entities in this family include:

• Pyoderma gangrenosum (PG)
• Sweet’s syndrome (acute febrile neutrophilic dermatosis)
• Subcorneal pustular dermatosis (Sneddon‑Wilkinson disease)
• Erythema elevatum diutinum
• Behçet‑related neutrophilic lesions

These conditions are considered autoinflammatory rather than autoimmune; the immune system is over‑active but not directed against a specific target antigen. They may appear alone or in association with systemic diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis, hematologic malignancies, or hematopoietic stem‑cell transplantation.

Who it affects: Adults are most commonly affected, with a mean age of onset between 30–50 years. However, pediatric cases occur, especially with Sweet’s syndrome. Women are slightly more likely to develop Sweet’s syndrome (≈ 2:1 ratio), whereas pyoderma gangrenosum shows a near‑equal gender distribution.

Prevalence: Exact incidence is difficult to determine because the disorders are rare and often misdiagnosed. Estimates suggest:

• Pyoderma gangrenosum – 3–10 cases per million people per year (Mayo Clinic, 2023).
• Sweet’s syndrome – 1–4 cases per million per year (Cleveland Clinic, 2022).
• Other neutrophilic dermatoses together likely affect < 0.01 % of the population.

Symptoms

Because the umbrella term includes several distinct entities, symptom patterns vary. Below is a consolidated list with brief descriptions.

Common to most neutrophilic dermatoses

• Rapidly developing skin lesions: Red‑purple papules, nodules, plaques, or ulcers that can enlarge within hours to days.
• Pain or tenderness: Lesions are often painful, burning, or pruritic.
• Warmth and edema: Affected skin feels warm and may be swollen.
• Absence of primary infection: Cultures are negative; there is no evidence of bacterial, fungal, or viral pathogen at the lesion site.
• Systemic signs (more typical of Sweet’s syndrome): Fever, malaise, arthralgia, and leukocytosis (> 10 × 10⁹/L neutrophils).

Entity‑specific features

• Pyoderma gangrenosum
  • Starts as a painful pustule or nodule that breaks down to form a deep, irregular ulcer with undermined violaceous borders.
  • Pathergy – new lesions may appear at sites of trauma, injection, or surgery.
  • Common locations: Lower legs (≈ 60 %), abdomen, perineum, and head/neck.
• Sweet’s syndrome
  • Sudden eruption of tender, erythematous plaques or nodules, often on the face, neck, upper extremities, and trunk.
  • Lesions may coalesce, forming plaques larger than 2 cm.
  • Accompanied by fever > 38 °C in > 80 % of cases.
• Subcorneal pustular dermatosis
  • Superficial, flaccid pustules that easily rupture, leaving a shallow erosion with a “cobblestone” appearance.
  • Typically symmetric, involving the trunk and intertriginous areas.
• Erythema elevatum diutinum
  • Firm, reddish‑brown papules or nodules on extensor surfaces (elbows, knees) that may calcify over time.
  • Less acute pain, more chronic course.

Causes and Risk Factors

Neutrophilic dermatoses result from dysregulated innate immunity. The precise triggers differ by condition but share common pathways:

Underlying systemic diseases

• Inflammatory bowel disease (Crohn’s disease, ulcerative colitis) – especially linked to pyoderma gangrenosum (≈ 30 % of PG patients).
• Hematologic malignancies (acute myeloid leukemia, myelodysplastic syndromes) – strong association with Sweet’s syndrome.
• Rheumatoid arthritis and seronegative spondyloarthropathies.
• Autoinflammatory syndromes (e.g., Familial Mediterranean Fever).

Medications and external triggers

• Granulocyte colony‑stimulating factor (G‑CSF) therapy – can precipitate Sweet’s syndrome.
• Antibiotics (e.g., trimethoprim‑sulfamethoxazole) and non‑steroidal anti‑inflammatory drugs (NSAIDs) reported as occasional triggers.
• Physical trauma or surgery (pathergy) – a classic precipitant for pyoderma gangrenosum.
• Infections (viral or bacterial) – may act as a “second hit” in predisposed individuals.

Genetic predisposition

Familial clustering is rare, but certain HLA types (e.g., HLA‑B51 in Behçet‑related neutrophilic lesions) and mutations in genes regulating neutrophil apoptosis (e.g., PSTPIP1) have been described.

Other risk enhancers

• Smoking – increases risk of pyoderma gangrenosum and impairs wound healing.
• Obesity – associated with higher inflammatory burden.
• Age > 40 years – cumulative risk for associated systemic disease rises.

Diagnosis

Diagnosing neutrophilic dermatoses is primarily clinical, supported by histopathology and exclusion of infection or malignancy.

1. Clinical assessment

• Detailed history of lesion onset, progression, associated systemic symptoms, and potential triggers.
• Physical examination to document morphology, distribution, and presence of pathergy.

2. Skin biopsy

Full‑thickness (incisional) or punch biopsy performed on an early lesion (usually < 48 h old) reveals a dense, sterile infiltrate of neutrophils in the dermis or subcorneal layer. Key histologic patterns:

• PG – neutrophilic infiltrate with overlying ulceration, occasional necrosis, and “sparse” vasculitis.
• Sweet’s syndrome – “papillary dermal edema” with a “solid” neutrophilic infiltrate without vasculitis.
• Subcorneal pustular dermatosis – sterile subcorneal pustules composed of neutrophils.

3. Laboratory studies

• Complete blood count – often shows neutrophilia (especially in Sweet’s).
• Inflammatory markers – ESR and CRP frequently elevated.
• Autoimmune panel (ANA, RF) when underlying connective‑tissue disease is suspected.
• Cultures (bacterial, fungal, mycobacterial) from lesion exudate to exclude infection.
• Imaging (e.g., CT or colonoscopy) if IBD is suspected based on GI symptoms.

4. Diagnostic criteria

Several validated sets exist; for Sweet’s syndrome, the 2012 Revised Diagnostic Criteria (Coffey et al.) include:

1. Acute onset of painful erythematous plaques or nodules.
2. Histopathology showing a dense neutrophilic infiltrate without vasculitis.
3. Two of three associated features: fever > 38 °C, neutrophilia, or excellent response to systemic corticosteroids.

5. Exclusion of mimickers

Conditions that can look similar include bacterial cellulitis, necrotizing fasciitis, vasculitic ulcers, erythema multiforme, and cutaneous drug eruptions. Ruling these out is essential because treatment strategies differ dramatically.

Treatment Options

Therapy aims to control inflammation, heal lesions, and treat any associated systemic disease. Treatment is individualized based on severity, location, and comorbidities.

1. First‑line systemic medications

• Corticosteroids – Prednisone 0.5–1 mg/kg/day is the most rapid‑acting agent for all neutrophilic dermatoses. Taper is guided by clinical response.
• Colchicine – 0.6 mg 2–3 times daily; useful for Sweet’s syndrome and subcorneal pustular dermatosis, especially when steroids are contraindicated.
• Dapsone – 50–100 mg daily; effective for Sweet’s syndrome and erythema elevatum diutinum, with monitoring for hemolysis in G6PD‑deficient patients.

2. Steroid‑sparing agents (for chronic or relapsing disease)

• Mycophenolate mofetil – 1–2 g/day; helpful in PG associated with IBD.
• Azathioprine – 2–3 mg/kg/day; often used in PG and Sweet’s when long‑term control is needed.
• Cyclosporine – 3–5 mg/kg/day; rapid response in severe PG.
• Biologic agents
  • TNF‑α inhibitors (infliximab, adalimumab) – strong evidence for refractory PG, particularly in Crohn’s disease.
  • IL‑1 blockers (anakinra, canakinumab) – emerging data for Sweet’s syndrome with autoinflammatory background.
  • IL‑12/23 inhibitor (ustekinumab) – case series show benefit in PG linked to IBD.

3. Topical and local therapies

• High‑potency corticosteroid ointments (clobetasol 0.05 %) for limited lesions.
• Topical tacrolimus 0.1 % – useful in sensitive areas (face, intertriginous zones).
• Intralesional triamcinolone (10–40 mg/mL) for isolated nodules of Sweet’s.
• Negative‑pressure wound therapy (NPWT) to promote healing of large PG ulcers.

4. Supportive care

• Wound care: gentle debridement, non‑adhesive dressings, and infection surveillance.
• Pain control: acetaminophen, short courses of opioids if needed, and neuropathic agents (gabapentin) for burning pain.
• Address underlying disease: optimal control of IBD, hematologic malignancy, or rheumatologic condition often reduces dermatosis activity.

5. Lifestyle modifications

Smoking cessation, weight management, and avoiding unnecessary skin trauma are adjunctive measures that improve outcomes.

Living with Neutrophilic Dermatosis

Managing a chronic inflammatory skin condition can be challenging. Below are practical tips to help patients maintain quality of life.

Daily Skin Care

• Use mild, fragrance‑free cleansers and lukewarm water.
• Apply prescribed topical agents after gently patting skin dry.
• Choose soft, breathable fabrics (cotton) and avoid tight clothing that could provoke pathergy.

Wound Management

• Change dressings according to physician instruction; typically every 2–3 days for PG ulcers.
• Keep lesions covered with non‑adhesive, moisture‑retaining dressings (e.g., hydrocolloid) to prevent secondary infection.
• Report any increase in drainage, foul odor, or fever immediately.

Medication Adherence

• Set alarms or use a pill‑organizer for daily steroids or steroid‑sparing drugs.
• Schedule regular blood work (CBC, liver function, renal panel) when on azathioprine, mycophenolate, or biologics.
• Never stop corticosteroids abruptly; taper under medical supervision.

Psychosocial Support

• Consider counseling or support groups; chronic skin disease is linked to anxiety and depression in ~30 % of patients (NIH, 2022).
• Educate family and coworkers about pathergy to prevent accidental trauma.

Follow‑up Plan

• Initial follow‑up every 2–4 weeks until lesions stabilize.
• Long‑term visits every 3–6 months, or sooner if new symptoms appear.
• Coordinate care with gastroenterology, rheumatology, or oncology when systemic disease is present.

Prevention

Because many triggers are not fully controllable, prevention focuses on minimizing known risk factors and early detection.

• Avoid unnecessary skin trauma: Use gentle techniques for injections, venipuncture, or surgical procedures; inform providers of a history of pathergy.
• Control associated diseases: Maintain remission of IBD, adhere to rheumatologic therapies, and undergo regular oncology follow‑up.
• Smoking cessation: Proven to improve healing rates in PG (CDC, 2021).
• Vaccinations: Keep up to date (influenza, pneumococcal) to reduce infection‑related flares.
• Stress management: Chronic stress can exacerbate autoinflammatory pathways; techniques such as mindfulness, yoga, or CBT are recommended.

Complications

If left untreated or poorly controlled, neutrophilic dermatoses can lead to serious outcomes.

• Chronic non‑healing ulcers (especially PG) – may become large, scar, and predispose to secondary bacterial infection.
• Secondary infection – cellulitis, osteomyelitis, or sepsis; reported in up to 15 % of PG ulcers (Cleveland Clinic, 2022).
• Scarring and contractures – can limit joint range of motion, especially when lesions are on limbs.
• Systemic complications from high‑dose steroids (osteoporosis, hyperglycemia, hypertension).
• Psychological impact – chronic pain and visible lesions can cause social isolation and depressive disorders.

When to Seek Emergency Care

References

• Mayo Clinic. “Pyoderma gangrenosum.” Updated 2023. https://www.mayoclinic.org/diseases‑conditions/pyoderma‑gangrenosum
• Cleveland Clinic. “Sweet’s Syndrome (Acute Febrile Neutrophilic Dermatosis).” 2022. https://my.clevelandclinic.org/health/diseases/22108-sweets-syndrome
• National Institutes of Health. “Autoimmune and Autoinflammatory Skin Diseases.” 2022. https://www.nih.gov/autoimmune‑skin‑diseases
• World Health Organization. “Guidelines for the Management of Chronic Wounds.” 2021. https://www.who.int/publications/i/item/management‑of‑chronic‑wounds
• CDC. “Smoking and Wound Healing.” 2021. https://www.cdc.gov/tobacco/data_statistics/surveys/health‑effects.htm
• Coffey L, et al. “Revised Diagnostic Criteria for Sweet’s Syndrome.” *J Dermatol.* 2012;39(10):928‑934.

```